Vimentin Protein In Situ Expression Predicts Less Tumor Metastasis and Overall Better Survival of Endometrial Carcinoma
Table 1
Clinicopathological characteristics of the 341 presented EC cases.
Characteristics
Vimentin negative
Vimentin positive
value
Age (years)
58 (30-93)
60 (37-79)
57 (30-93)
0.017
Gestation
2 (0-8)
2 (0-5)
2 (0-8)
0.614
Parity
1 (0-4)
1 (0-3)
1 (0-4)
0.409
FIGO stage
<0.001
I
250
35 (54.69%)
215 (77.62%)
II
25
3 (4.68%)
22(7.94%)
III
52
19 (29.68%)
33 (11.91%)
IV
14
7 (10.95%)
7 (2.53%)
Postmenopause
0.921
Yes
214
40 (62.50%)
174 (62.82%)
No
127
24(37.50%)
103(37.18%)
Diabetes
0.435
Yes
79
17 (26.56%)
62 (22.38%)
No
262
47 (73.44%)
215 (77.62%)
Hypertension
0.289
Yes
163
34 (54.13%)
99 (35.74%)
No
178
30 (46.87%)
148 (64.26%)
Hypercholesteremia
0.275
Yes
75
17 (27.42%)
58 (21.40%)
No
258
45 (72.58%)
213 (78.60%)
NA
8
BMI (kg/m2)
0.339
<18.5
7
3 (4.76%)
4 (1.45%)
18.5-23.9
87
17(26.98%)
70 (25.45%)
24.0-27.9
113
22 (34.92%)
91 (33.09%)
≥28.0
131
21 (33.34%)
110 (40.01%)
NA
2
Hypertriglyceridemia
0.667
Yes
32
5 (8.07%)
27 (10.00%)
No
230
57 (91.93%)
243 (90.00%)
NA
9
Histologic grade
<0.001
1
106
12 (18.75%)
94 (34.18%)
2
162
24 (37.50%)
138 (50.18%)
3
39
11 (17.18%)
28 (10.18%)
High grade
32
17 (26.57%)
15 (5.46%)
NA
2
Histological type
<0.001
I
309
47 (73.43%)
262 (94.58%)
II
32
17 (26.57%)
15 (5.42%)
Positive lymph nodes
<0.001
Yes
39
16 (25.00%)
23 (8.30%)
No
302
48 (75.00%)
254 (91.70%)
LVSI
0.006
Yes
68
21 (32.81%)
47 (16.97%)
No
219
43 (67.19%)
230 (83.03%)
MI
0.020
<50%
231
34 (53.13%)
197 (71.12%)
>50%
110
30 (46.87%)
80 (28.88%)
Vital state
0.001
Alive
300
50 (79.37%)
250 (94.34%)
Dead
28
13(20.63%)
15 (5.66%)
NA
13
EC: endometrial carcinoma; FIGO: Federation International of Gynecology and Obstetrics Association; BMI: body mass index; NA: NA means that the data is not available; LVSI: lymph vascular space invasion; MI: myometrium invasion. The ages in the table are in years and are shown as medians and ranges.
